# Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

> **NCT03006770** · PHASE3 · COMPLETED · sponsor: **Pluristem Ltd.** · enrollment: 213 (actual)

## Conditions studied

- Critical Limb Ischemia (CLI)

## Interventions

- **BIOLOGICAL:** PLX-PAD
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03006770
- **Lead sponsor:** Pluristem Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-22
- **Primary completion:** 2021-03-03
- **Final completion:** 2022-04-20
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2024-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006770, "Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03006770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*